| Company Name: |
Sigma-Aldrich
|
| Tel: |
021-61415566 800-8193336 |
| Email: |
orderCN@merckgroup.com |
| Products Intro: |
Product Name:PNU-282987 hydrate
Purity:solid, >=98% (HPLC) Package:10MG Remarks:P6499-10MG
|
| Company Name: |
Merck KGaA
|
| Tel: |
21-20338288 |
| Email: |
ordercn@merckgroup.com |
| Products Intro: |
Product Name:PNU-282987 hydrate
|
| Company Name: |
Riedel-de Haen AG
|
| Tel: |
800 558-9160 |
| Email: |
|
| Products Intro: |
Purity:solid, ≥98% (HPLC)
|
| Company Name: |
SIGMA-RBI
|
| Tel: |
800 736 3690 (Orders) |
| Email: |
|
| Products Intro: |
|
|
| | N-(3R)-1-AZABICYCLO[2.2.2]OCT-3-YL-4-CHLORO-BENZAMIDE MONOHYDROCHLORIDE HYDRATE Basic information |
| | N-(3R)-1-AZABICYCLO[2.2.2]OCT-3-YL-4-CHLORO-BENZAMIDE MONOHYDROCHLORIDE HYDRATE Chemical Properties |
| storage temp. | 2-8°C | | solubility | DMSO: >10mg/mL | | form | solid | | InChI | 1S/C14H17ClN2O.ClH.H2O/c15-12-3-1-11(2-4-12)14(18)16-13-9-17-7-5-10(13)6-8-17;;/h1-4,10,13H,5-9H2,(H,16,18);1H;1H2/t13-;;/m0../s1 | | InChIKey | OCWLMMBVXIESNP-GXKRWWSZSA-N | | SMILES | Cl[H].[H]O[H].Clc1ccc(cc1)C(=O)N[C@H]2CN3CCC2CC3 |
| WGK Germany | 3 | | Storage Class | 11 - Combustible Solids |
| | N-(3R)-1-AZABICYCLO[2.2.2]OCT-3-YL-4-CHLORO-BENZAMIDE MONOHYDROCHLORIDE HYDRATE Usage And Synthesis |
| Uses | PNU-282987 hydrate has been used to check its activity in wound repair by inhibiting AGE (advanced glycation end products)-mediated tumor necrosis factor-α (TNF-α) production in a streptozotocin (STZ)-induced diabetic mouse model. It has also been used to evaluate the effects of nicotinic α-7 acetylcholine receptor (nAChRα7) activation on non-diabetic wound healing. | | Biochem/physiol Actions | Decreased expression of a homomeric alpha7 nicotinic acetylcholine receptor (nAChR) is connected with inability to process sensory information in schizophrenia. PNU-282987 is a novel selective agonist of the alpha7 nAChR that evoked whole-cell currents from cultured rat hippocampal neurons that were sensitive to the selective alpha7 nAChR antagonist methyllycaconitine (MLA) and enhanced GABAergic synaptic activity. The alpha7 nAChR agonist PNU-282987 improves auditory gating and enhances hippocampal oscillatory activity. These results provide further support for the concept that drugs that selectively activate alpha7 nAChRs may offer a novel, potential pharmacotherapy in treatment of schizophrenia. |
| | N-(3R)-1-AZABICYCLO[2.2.2]OCT-3-YL-4-CHLORO-BENZAMIDE MONOHYDROCHLORIDE HYDRATE Preparation Products And Raw materials |
|